---
title: "Mentari Therapeutics climbs 9%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/305477561.md"
description: "Mentari Therapeutics rose 8.99% to US$20.00."
datetime: "2026-11-13T14:44:14.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/305477561.md)
  - [en](https://longbridge.com/en/news/305477561.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/305477561.md)
generator: "portal-rs"
---

# Mentari Therapeutics climbs 9%

Mentari Therapeutics (MTRI.US) climbed nearly **9%** during regular trading to **$20.00**.

The Nasdaq Composite is up 2.90% over the past five sessions.

Mentari completed its merger with InMed Pharmaceuticals on Nov. 6, 2026, and released pro forma combined financial statements. As of June 30, 2026, the company reported total cash of $478.12 million, total assets of $478.78 million and liabilities of $11.42 million. The net loss for the first half of 2026 was $37.29 million.

Based on public media reports. AI-generated; not investment advice.

### Related Stocks

- [MTRI.US](https://longbridge.com/en/quote/MTRI.US.md)

## Related News & Research

- [Mentari Therapeutics' Total Liabilities Rise to $78.61 Million From $10.26 Million at Year-End](https://longbridge.com/en/news/305668280.md)
- [Wedbush initiates coverage of Mentari Therapeutics at Outperform, sets price target at $33](https://longbridge.com/en/news/305469432.md)
- [MTRI: PACAP/CGRP pipeline targets more effective, less frequent migraine prevention](https://longbridge.com/en/news/305818527.md)
- [Jefferies initiates coverage of Mentari Therapeutics at Buy, sets price target at $30](https://longbridge.com/en/news/305028486.md)
- [Mentari Therapeutics Publishes Pro Forma Combined Financial Statements With InMed Pharmaceuticals](https://longbridge.com/en/news/305072970.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**